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Preservation of beta cell against apoptosis is one of the therapeutic benefits of the glucagon-like peptide-1 (GLP1) antidiabetic
mimetics for preserving the functional beta cell mass exposed to diabetogenic condition including proinflammatory cytokines.The
mitogen activated protein kinase 10 also called c-jun amino-terminal kinase 3 (JNK3) plays a protective role in insulin-secreting
cells against death caused by cytokines. In this study, we investigated whether the JNK3 expression is associated with the protective
effect elicited by the GLP1 mimetic exendin 4. We found an increase in the abundance of JNK3 in isolated human islets and INS-1E
cells cultured with exendin 4. Induction of JNK3 by exendin 4 was associated with an increased survival of INS-1E cells. Silencing
of JNK3 prevented the cytoprotective effect of exendin 4 against apoptosis elicited by culture condition and cytokines.These results
emphasize the requirement of JNK3 in the antiapoptotic effects of exendin 4.
1. Introduction
Preservation of mechanisms underlying adaptation of beta
cells mass and function is critical for glucose homeostasis,
as the decline in functional beta cells mass is a key feature
of the development of diabetes [1–5]. The incretin hormone
glucagon-like peptide-1 (GLP1) plays an instrumental role in
the control of beta cell mass and function [6–8]. Alteration
of beta cell sensitivity to GLP1 is thought to contribute to
the loss of functional beta cell mass in diabetes in both lean
and obese individuals [9–11]. Beta cell abnormalities in the
GLP1 sensitivity have been associated with a reduction in the
GLP1 receptor expression in some animal models of diabetes
[12, 13]. Administration of GLP1 improves beta cell survival
in animal model of diabetes [14, 15]. A wealth of in vitro and
in vivo studies show that this prosurvival effect is achieved
by inhibiting beta cells apoptosis elicited by diabetogenic
stressors such as proinflammatory cytokines [6, 16–23]. The
effect achieved by the GLP1 and its analogs results from the
activation of kinases and/or scaffold proteins, which in turn
promote an antiapoptotic signaling cascade [6, 18, 19, 24–28].
One of the major kinases activated by GLP1 and its mimetic
exendin 4 is the protein kinase B/AKT [16, 17, 27]. Activation
of AKT by GLP1 results from the increased abundance of
the insulin receptor substrate 2 (IRS2) [27]. In beta cells,
the expression of IRS2 is controlled by the mitogen activated
protein kinase 10 also called c-jun amino-terminal kinase
3 (JNK3) [29, 30]. Silencing of JNK3 by interference RNA
dramatically reduces the IRS2 abundance in INS-1E cells [29].
As a result of JNK3 depletion an increase in cytokine-induced
apoptosis ensues [29, 30]. In view of these data, the goal of
this study was to investigate whether the JNK3 content is
associated with beta cell protection achieved by the GLP1
mimetic exendin 4.
2. Material and Methods
2.1. Cell Culture, Human Islets Isolation, and Transfection.
The rat insulin-secreting cell line INS-1E was maintained
in RPMI 1640 medium supplemented with 10% fetal calf
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serum (FCS) (PAA laboratories, GE Healthcare, Velizy-
Villacoublay, France), 1mM sodium pyruvate, 50𝜇M 𝛽-
mercaptoethanol, and 10mMHepes [31]. Human pancreases
were harvested from adult brain-dead donors in accordance
with French regulations and with the local Institutional
Ethical Committee from the “Centre Hospitalier Re´gional
et Universitaire de Lille.” Pancreatic islets were isolated
after ductal distension of the pancreas and digestion of the
tissue as described previously [32]. All experiments were
carried out at least on islets with a purity of and viability
>80%. Purified islets were cultured in CMRL 1066 medium
(Gibco BRL, Life Technologies) containing 0.625% free fatty
acid human serum albumin (Roche Diagnostics), penicillin
(100 𝜇UI/mL), and streptomycin (100 𝜇g/mL). The siRNA
duplexes directed against JNK3 (siJNK3) or siRNA control
against GFP (siGFP) were previously described [29–31]. The
siRNA duplexes were introduced using the Lipofectamine
2000 (Life Technology, Saint Aubin, France) as described
[29, 30].
2.2. Western Blotting Experiments. INS-1E and isolated hu-
man islets cells were scrapped in cold PBS buffer and
cell pellets were incubated 30min on ice in lysis buffer
(20mMTris acetate pH 7, 0.27mM sucrose, 1% Triton X-100,
1mM EDTA, and 1mM EGTA, 1mM DTT) supplemented
with antiproteases and antiphosphatases (Roche, Meylan,
France). Cell lysates were centrifugated 15min at 18,000 g
and supernatants were used to analyze proteins. Protein
extracts were solubilized in Laemmli buffer (40% glycerol,
20% 𝛽-mercaptoethanol, 8% SDS, 0.02% bromophenol blue,
0.25mM Tris-HCl, pH 6.8) and denatured 10min at 95∘C
before loading onto the gel. Proteins were separated on 10%
SDS-polyacrylamide gel and electrically blotted to nitro-
cellulose membranes. The proteins were detected after an
overnight incubation of the membrane at 4∘C with the spe-
cific primary antibodies against JNK3 (dilution 1 : 1000; Cell
Signaling Technology, MA, USA), JNK2 (dilution 1 : 1000;
Cell Signaling Technology, MA, USA), 𝛽-actin (1 : 5000;
Sigma, Saint Quentin, France), or 𝛼-tubulin (1 : 5000; Sigma,
Saint Quentin, France), diluted in buffer containing 0.1%
Tween 20 with either 2% milk (for JNK3) or 5% BSA (for
JNK2) or 5% milk (for 𝛽-actin and 𝛼-tubulin). Proteins were
visualized with IRDye800 or IRDye700 (Eurobio, Les Ulis,
France) as secondary antibodies. Quantification was per-
formed using theOdyssey infrared imaging system (Eurobio)
[29, 30].
2.3. Apoptosis Assay. Apoptosis was evaluated in cells trans-
fected with the siRNAs and exposed to a cytokine cock-
tail (R&D Systems, Minneapolis, MN, USA) of rat IL-
1𝛽 (10 ng/mL), mouse TNF𝛼 (25 ng/mL), and rat IFN𝛾
(150 ng/mL) for 24 h. Apoptosis was determined by scoring
cells displaying pycnotic nuclei (visualized with Hoechst
33342) [31]. The counting was performed blindly by three
different experimenters.
2.4. Statistical Analysis. ANOVA was used for statistical sig-
nificance, followed by the post hoc Bonferroni test (Dunnett’s
test) when experiments included more than two groups. The
level of significance was set at 𝑃 < 0.05 (SAS statistical
package; SAS, Carry, NC).
3. Results
3.1. Exendin 4 Increases the JNK3 Abundance in Isolated
Human Islets and INS-1E. Several studies, including ours,
have shown that theGLP1 receptor agonists prevent apoptosis
elicited by prolonged exposure with cytokines [21, 23, 31].
Typically, the cytoprotective effect of the GLP1 mimetic
is achieved through induction of key prosurvival proteins
[6, 25]. In this regard we questioned whether exendin 4
increased the abundance of JNK3. We found that exposure
of isolated human islets cells to exendin 4 elevated the
JNK3 abundance as revealed by western blotting analysis
(Figure 1(a)). The increase in the JNK3 protein started as
early as 2 hr and declined after 4 hr (Figure 1(a)). Induction
of JNK3 by exendin 4 was observable at 10 nM but was
optimal at 50 nM (Figure 1(b)). Western blotting experiment
confirmed elevation of JNK3 protein by exendin 4 in INS-1E
cells (Figure 1(c)). However, induction of JNK3 by the GLP1
receptor agonist came later (after 4 hr of incubation) and
persisted until 24 h treatment (Figure 1(c)).
3.2. JNK3 Is Required for the Cytoprotective Effects of Exendin
4 in INS-1E Cells. We next investigated whether JNK3 was
required for the cytoprotective effect of exendin 4. To this end,
INS-1E cellswere transfectedwith the duplex siRNAsdirected
against JNK3 mRNA (siJNK3) [29, 30]. The latter efficiently
and selectively silenced the expression of JNK3 in INS-1E
cells (Figure 2(a)). As anticipated, incubation of the cells with
cytokines for 24 hr elicited a 2-fold increase in apoptosis
(Figure 2(b)). Exendin 4 efficiently reduced death evoked by
culture conditions and cytokines (Figure 2(b)). As previously
observed [29, 30], silencing of JNK3 potentiated cytokines-
induced apoptosis (Figure 2(b)). In addition, diminution of
JNK3by siJNK3 abolished the protective effects accomplished
by exendin 4 (Figure 2(b)). These data point out that JNK3
levels are pivotal for the coupling of exendin 4 and protection
of cells against apoptosis evoked by cytokines.
4. Discussion
There is a growing body of evidence that the GLP1 and
its mimetics trigger cytoprotective effects on beta cells by
stimulating the abundance of antiapoptotic proteins [6, 17,
25–27, 31, 33]. Several reports have now delineated a role
for JNK3 as a key player in protecting beta cells against
apoptosis [29, 30]. A hallmark of this claim is that selective
silencing of JNK3 increases apoptosis induced by cytokines
[29, 30]. Inversely, we questioned whether the JNK3 content
could be stimulated by the GLP1 mimetic exendin 4. We
found that exposure of isolated human islets to exendin
4 increases the JNK3 protein content. Although the anti-
apoptotic mechanisms activated by the GLP1 mimetics are
globally similar between human islets and the rat insulin-
secreting INS-1E cells [6, 17, 25, 26, 31], the spatial and
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Figure 1:The effect of exendin 4 on the JNK3 content. JNK3 abundance in (a) isolated human islets (from three different donors) culturedwith
50 nM exendin 4 for the indicated times or (b) with different exendin 4 concentrations for 4 hrs. (c) INS-1E cells cultured with 50 nM exendin
4 for the indicated times. For western blotting experiments, protein extracts (50𝜇g) were loaded into a polyacrylamide gel electrophoresis.
Immunoblotting was achieved using the anti-JNK3 and anti-𝛽-actin antibodies. The data is one representative experiment out of three.
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Figure 2: Impact of the JNK3 silencing on the protective effects of exendin 4. INS-1E cells were transfected with the siRNA duplex directed
against JNK3 (siJNK3) or control siRNA (siGFP, Ctrl). (a) For western blotting analysis of the JNK3 level, total proteins were prepared 48 hr
after transfection. Immunoblotting was done using the anti-JNK3, anti-JNK2, and anti-𝛼-tubulin antibodies (b) for scoring death; the cells
were preincubated 24 hr after transfection with 50 nM exendin 4 for 8 hr.The rate of apoptosis was scored by counting pycnotic nuclei in INS-
1E cells exposed for 16 hr to the cocktail of cytokines including 10 ng/mL IL-1𝛽, 15 ng/mL TNF𝛼, and 150 ng/mL IFN𝛾. Results are expressed
as mean ± SEM of 3 independent experiments. ∗𝑃 < 0.05; ∗∗∗𝑃 < 0.001.
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temporal regulation of certain pathways evoked by GLP1
and its analogs may be species-specific. Different temporal
activation of the antiapoptotic ERKpathway between isolated
human islets and INS-1E cells has been shown in response
to RF26a RFamide peptide [34]. While ERK is activated by
the peptide in human islets and INS-1E cells, peptide-induced
ERK activation is more prolonged in INS-1E cells [35]. One
study has shown that beta cells behaviour in response to
GLP1 is different between human and rodent islets [36]. GLP1
promotes cooperation and connectedness between beta cells
within human islets whereas it does not do this in rodent cells
[36]. This difference may elicit some changes in the spatial
and temporal regulation of genes expression and pathways.
In this regard, we observed that induction of JNK3 content
by exendin 4 was faster and declined more rapidly in human
islets when compared to INS-1E cells.
The induction of JNK3 in human islets and INS-1E cells
led us to ask whether such phenomenon contributed to the
protective effects elicited by exendin 4 against apoptosis.
One clue was that the increase of JNK3 content in cultures
of INS-1E cells for 24 h was associated with a significant
reduction in apoptosis under normal culture condition. This
antiapoptotic effect achieved by the GLP1 mimetic was abol-
ished when JNK3 content was reduced by siRNA. We have
previously published that cytokine treatment of INS-1E cells
with cytokines worsens death caused by apoptosis [31]. The
rise of death induced by cytokines is alleviated by coculturing
the cells with exendin 4 [31]. The experiments unveiled that
protection of INS-1E cells by exendin 4 against cytokine-
induced apoptosis is abolished when the JNK3 abundance is
attenuated.
Several key transcription factors and signalling proteins
including protein kinase A (PKA), PKB/AKT, PKC-zeta,
ERK, endoplasmic reticulum stress, and epidermal growth
factor receptor are involved in the cytoprotective effects
achieved by the GLP1 mimetics [6, 18, 19, 24–26]. Abdelli
and coauthors have shown a reduction in the expression of
insulin receptor substrate 2 (IRS2) and Akt activation upon
silencing of JNK3 [29, 30]. However, JNK3 ismainly localized
in the nucleus of beta cells [29, 30], suggesting that IRS2
cannot be the only target of the kinase. Future studies are
needed to identify other targets of JNK3 that are required
for the antiapoptotic effects of exendin 4. Such investiga-
tion could uncover novel protective pathways of beta cells
and eventually lead to innovative antidiabetic therapeutic
targets.
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